Morgan Stanley Maintains Underweight, $211 Target On Biogen As Firm Notes '2Q Beats But Doesn't Change Our LT View';  Firm Notes 'With our tail concerns around Tecfidera IP, MS pricing, Rituxan biosimilars and Spinraza competition unchanged, we remain UW'